HBM BIOVENTURES CAYMAN LTD 13D/13G Filings for Ambrx Biopharma Inc. (AMAM)

HBM BIOVENTURES CAYMAN LTD 13D and 13G filings for Ambrx Biopharma Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2023-02-14
4:02 pm
Sale		 2022-12-31 13G Ambrx Biopharma Inc.
AMAM		 HBM BIOVENTURES CAYMAN LTD 8,400,000
3.100%		 -8,456,567decrease
(-50.17%)		 Filing
2022-02-11
4:03 pm
Sale		 2021-12-31 13G Ambrx Biopharma Inc.
AMAM		 HBM BIOVENTURES CAYMAN LTD 16,856,567
6.900%		 -898,156decrease
(-5.06%)		 Filing
2021-07-02
4:00 pm
Purchase		 2021-06-22 13G Ambrx Biopharma Inc.
AMAM		 HBM BIOVENTURES CAYMAN LTD 17,754,723
6.700%		 17,754,723increase
(New Position)		 Filing